IDH1 and central nervous system cancer: The information gleaned from the methylation status and expression profile of the PD-L1 gene in gliomas is expected to help stratify patients, so that they can receive more appropriate and targeted treatment options, such as immune checkpoint inhibitors, that are specific for IDH1 wildtype gliomas.